Oral Wegovy’s Pending Approval Puts Spotlight on Viability of High-Dose Peptides
While the 10-fold increase in dose over injectable Wegovy has raised questions about the launch, Novo Nordisk has assured investors it has the manufacturing capacity to roll out oral semaglutide without restrictions on supply.Read more:
biospace.comBiotechnology